Product Description

Avangio (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF).

Avangio contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Avangio is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium and has a molecular weight of approximately 149kDa.

Indications

  • Metastatic Colorectal Cancer (mCRC)
  • Non-squamous Non-small Cell Lung Cancer (NSCLC)
  • Glioblastoma (GBM)
  • Metastatic Renal Cell Carcinoma (mRCC)
  • Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
  • Metastatic Breast Cancer (mBC)

Storage

  • Store at 2°C to 8°C
  • Protect from light
  • Do not freeze or shake

Shelf-life

24 months from the date of manufacture

Product Name

Avangio


Generic Name

Bevacizumab


Strengths Avaliable

100 mg in 4mL, 400 mg in 16mL